TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05892653
Drug: ABM-1310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed.
Study: NCT06513624
Drug: Denosumab / Zoledronic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.
Study: NCT05030857
Drug: GLPG4716
Approvals — FDA: no, EMA: no, PMDA: no
Description: From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
Study: NCT06010732
Drug: 0 ppm F (placebo, negative control)
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Study: NCT05129423
Drug: MTPS9579A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTPS9579A will be administered.
Study: NCT05129423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched with MTPS9579A will be administered.
Study: NCT04662580
Drug: ARX517
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
Study: NCT03720483
Drug: N-acetyl cysteine then Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive N-acetyl cysteine first followed by Placebo
Study: NCT03720483
Drug: Placebo then N-acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive Placebo first followed by N-acetyl cysteine
Study: NCT05861310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
Study: NCT05239728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06307600
Drug: RD06-03 cell injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this intervention will use RD06-03 cell injection with 3 dose dose 1: 1×10\^5 CAR+ T Cells/kg dose 2: 3×10\^5 CAR+ T Cells/kg dose 3: 5×10\^5 CAR+ T Cells/kg Dosage form: IV injection Frequency of administration：1 time
Study: NCT06008028
Drug: BR1015
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06008028
Drug: BR1015-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06008028
Drug: BR1015-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06252194
Drug: Metformin and doxycycline
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg tablet twice daily
Study: NCT05035810
Drug: Corticosteroid Injection given in A-B order
Normalized name: Orderable Drug Form
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
Study: NCT05511519
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet manufactured to match ATI-450 in appearance
Study: NCT05923177
Drug: SPECT
Normalized name: Spectrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single injection of \[123I\] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.
Study: NCT05035810
Drug: Procedure: Corticosteroid Injection given in B-A order
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
Study: NCT04216290
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06319118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.
Study: NCT06066528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly subcutaneous injection
Study: NCT05260021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06521476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo daily for 7 days
Study: NCT06201247
Drug: JD123 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
Study: NCT05523297
Drug: Frozen Plasma Product, Human
Normalized name: Frozen plasma product, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
Study: NCT06528431
Drug: Clinical tapering strategy
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
Study: NCT04718961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules matched to study drug minus active substance.
Study: NCT06557174
Drug: mycophenolate mofetil， MMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral 0.2g
Study: NCT04982926
Drug: TAS2940
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.
Study: NCT04982926
Drug: TAS2940
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
Study: NCT05556291
Drug: Combinations of Oral Blood Glucose Lowering Drugs
Normalized name: Combinations of oral blood glucose lowering drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ertugliflozin and Sitagliptin
Study: NCT06151431
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT06151431
Drug: α-adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT05936268
Drug: Genakumab for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/1ml/bottle
Study: NCT05293964
Drug: SIM0270
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIM0270 is an oral, selective estrogen receptor degrader (SERD)
Study: NCT06242795
Drug: 7% Hypertonic Saline via nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
Study: NCT05838573
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
Study: NCT05660681
Drug: polyethylene glycol 400 0.4%/propylene glycol 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop with active agents from the OTC Monograph.
Study: NCT05437263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT05670847
Drug: Exogenous ketone ester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
Study: NCT06517823
Drug: Etoricoxib fixed dose
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill of 90 mg a day
Study: NCT02675842
Drug: Smoked Cannabis High CBD/low THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
Study: NCT06352424
Drug: Placebo for BI 1820237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for BI 1820237
Study: NCT05136690
Drug: MK-4334
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4334 250 mg capsule taken by mouth.
Study: NCT05136690
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch.
Study: NCT05136690
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken by mouth.
Study: NCT06352424
Drug: Placebo for BI 456906
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for BI 456906
Study: NCT06299124
Drug: RGT-419B
Approvals — FDA: no, EMA: no, PMDA: no
Description: RGT-419B will be administered orally
Study: NCT06680947
Drug: 610
Normalized name: AY-6108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injection.
Study: NCT06680947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injection.
Study: NCT02675842
Drug: Smoked Placebo Cannabis Low CBD/low THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
Study: NCT05171946
Drug: S.opt.FL COVID-19 pDNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose: (1mg) level
Study: NCT05893160
Drug: JAN101 SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
Study: NCT05171946
Drug: S.opt.FL COVID-19 pDNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-Dose: (2mg) level
Study: NCT05171946
Drug: S.opt.FL COVID-19 pDNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose: (4mg) level
Study: NCT06709417
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )
Study: NCT06708845
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT05653024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 puffs of placebo inhaler administered with spacer
Study: NCT05642507
Drug: AC01
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Focan LLC AFFEX CARE Hand Sanitizer(AC01-04-01)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC01 microtablets
Study: NCT06383572
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05578872
Drug: ANV419
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANV419 administered by intravenous (IV) infusion
Study: NCT06052748
Drug: AD-223B
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06052748
Drug: AD-223C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06052748
Drug: AD-223A Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06052748
Drug: AD-223B Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT06052748
Drug: AD-223C Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT05742698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
Study: NCT04855929
Drug: ANV419
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANV419 administered by intravenous (IV) infusion
Study: NCT05086250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
Study: NCT05086250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
Study: NCT06508827
Drug: Iron dextran 1000 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.
Study: NCT06331624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 4.5mg soft gel capsule
Study: NCT06497127
Drug: BW-00112
Approvals — FDA: no, EMA: no, PMDA: no
Description: BW-00112 or volume-matched placebo on Day 1 and Day 90
Study: NCT05356078
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class
Study: NCT06402630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Study: NCT05971862
Drug: SKI-G-801
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
Study: NCT06111521
Drug: LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06111521
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06251180
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Study: NCT06251180
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Study: NCT06031844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral film-coated tablets
Study: NCT04862221
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
Study: NCT04862221
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue
Study: NCT04862221
Drug: Placebo for prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue
Study: NCT04862221
Drug: Placebo for infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
Study: NCT05627375
Drug: Full-dose anticoagulant therapy (AC)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
Study: NCT05627375
Drug: Antiplatelet therapy (AP)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
Study: NCT05254574
Drug: 2.5% Diclofenac Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Study: NCT05030428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
Study: NCT05676684
Drug: Spironolactone + Dapagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C: Dapagliflozin 10 mg once daily plus Spironolactone 25mg/every other day or 25mg/day (can be adjusted according to potassium and renal function)
Study: NCT04354545
Drug: Xiidra (Lifitegrast ophthalmic solution) 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved lifitegrast opthalmic solution eye drop
Study: NCT04667377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04592744
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
Study: NCT05065463
Drug: AZD8233
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
Study: NCT05800873
Drug: EVER001
Approvals — FDA: no, EMA: no, PMDA: no
Description: A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
Study: NCT04794088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
Study: NCT04979442
Drug: RAIN-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
Study: NCT05642780
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
Study: NCT05522868
Drug: SB17170
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB17170 capsules, Oral administration 21days/cycle
Study: NCT05013034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
Study: NCT04872400
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
Study: NCT05700903
Drug: Gonadotropin Releasing Hormone Agonists (GNRH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of GnRH agonist
Study: NCT05700903
Drug: Androgen receptor (AR) inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of AR Inhibitor
Study: NCT05700903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet and injection
Study: NCT06066424
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by (IV) vein
Study: NCT04298983
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.
Study: NCT05529927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group.
Study: NCT05991349
Drug: IBI129
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Study: NCT05893537
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 123 participants will receive a single daily dose of placebo
Study: NCT05330455
Drug: GSK3965193
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3965193 will be administered
Study: NCT05330455
Drug: Placebo to match GSK3965193
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GSK3965193 will be administered